New drug combo aims to fight Hard-to-Treat prostate cancer
NCT ID NCT02123758
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called JNJ-56021927 combined with abiraterone acetate (Zytiga) and prednisone in 57 men with metastatic castration-resistant prostate cancer. The goal is to see how these drugs interact, check safety, and get an early look at effectiveness. All participants take the drugs by mouth daily for up to 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-56021927 (ARN-509) combined with abiraterone acetate and prednisone
What this could lead to
If successful, this could lead to a more effective treatment option for men with metastatic castration-resistant prostate cancer.
What could go wrong
This is an early phase 1 trial with only 57 participants, so results are preliminary. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Los Angeles, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Houston, Texas, United States
-
Study site
Vancouver, British Columbia, Canada
-
Study site
Montreal, Quebec, Canada
-
Study site
Rotterdam, Netherlands
-
Study site
Sutton, United Kingdom